INTRA-CELLULAR THERAPIES INC (ITCI)

US46116X1019 - Common Stock

72.395  -4.3 (-5.6%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
83.8M
267.54%		250.3M
198.69%		464.37M
85.53%		674.27M
45.20%
EBITDA
YoY % growth
-285.17M
-23.63%		-262.94M
7.80%		-158.853M
39.59%		-87.816M
44.72%
EBIT
YoY % growth
-285.7M
-23.57%		-263.6M
7.74%		-159.381M
39.54%		-84.117M
47.22%
Operating Margin
-340.93%-105.31%-34.32%-12.48%
EPS
YoY % growth
-3.50
-8.02%		-2.72
22.29%		-1.46
46.32%		-0.70
52.33%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		-0.33
27.46%
Revenue
Q2Q % growth		143.73M
50.82%
EBITDA
Q2Q % growth		-34.374MN/AN/AN/AN/A
EBIT
Q2Q % growth		-36.485M
24.62%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 -0.30
33.33%		-0.450.1533.56%
Q3 2023
Q2Q % growth		 -0.25
56.14%		-0.580.3356.70%
Q2 2023
Q2Q % growth		 -0.45
51.09%		-0.600.1525.25%
Q1 2023
Q2Q % growth		 -0.46
41.03%		-0.620.1625.60%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 132.099M
50.28%		138.38M-6.281M-4.54%
Q3 2023
Q2Q % growth		 126.2M
75.52%		121.62M4.58M3.77%
Q2 2023
Q2Q % growth		 110.8M
99.28%		108.78M2.02M1.86%
Q1 2023
Q2Q % growth		 95.3M
172.29%		93.824M1.476M1.57%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 7.19% -1.7% -32.07%
Revenue0% -0.8% 0% 0.1%